Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. General Discussion
  3. Citing patient preference in a patient profile
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

Citing patient preference in a patient profile

Scheduled Pinned Locked Moved General Discussion
2 Posts 2 Posters 11 Views 1 Watching
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • A Offline
    A Offline
    adelaidebaker
    wrote last edited by
    #1

    Hi PAAB,

    I’m looking for clarification regarding whether patient preference can be cited in a patient profile as an acceptable reason for switching to a different treatment.

    Specifically, if Canadian clinical guidelines indicate that patient preference is a legitimate consideration when selecting or switching medications, would it be acceptable to reference, for example, that a patient dislikes oral medications or has difficulty remembering to take pills—as a rationale for considering an injectable treatment instead?

    I understand that we must avoid any disparaging remarks about other products or dosage forms. However, if the rationale is grounded in patient preference and is consistent with guideline-based reasoning (even if “preference” is somewhat broadly defined), would this type of messaging be considered acceptable?

    Looking forward to your guidance on this.

    1 Reply Last reply
    0
    • Jennifer CarrollJ Offline
      Jennifer CarrollJ Offline
      Jennifer Carroll
      wrote last edited by
      #2

      Hello @adelaidebaker

      As a general principle, the clinical decision to prescribe or switch should be made based on clinical considerations. Patient preference can be a part of a patient profile but should not be positioned as the reason to prescribe or switch. Patient preference can be presented as a consideration, without drawing conclusions about clinical actions.
      With respect to the specific case presented in the question, the copy in the guidelines and the APS would have to be assessed at the time of submission. We’d caution that “broadly defined” may be problematic and that drawing inference around patient choice such as “difficulty remembering to take pills and therefore might prefer injections” would require statistically significant evidence from a published high quality source.

      1 Reply Last reply
      0
      Reply
      • Reply as topic
      Log in to reply
      • Oldest to Newest
      • Newest to Oldest
      • Most Votes


      • Login

      • Don't have an account? Register

      • Login or register to search.
      • First post
        Last post
      0
      • Categories
      • Recent
      • Tags
      • Popular
      • Users
      • Groups